Cardiac Sarcoidosis
Copyright © 2023 Elsevier Inc. All rights reserved..
Cardiac involvement is a major cause of morbidity and mortality in patients with sarcoidosis. It is important to distinguish between clinical manifest diseases from clinically silent diseases. Advanced cardiac imaging studies are crucial in the diagnostic pathway. In suspected isolated cardiac sarcoidosis, it's key to rule out alternative diagnoses. Therapeutic options can be divided into immunosuppressive agents, guideline-directed medical therapy, antiarrhythmic medications, device/ablation therapy, and heart transplantation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Clinics in chest medicine - 45(2024), 1 vom: 03. März, Seite 105-118 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ribeiro Neto, Manuel L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiac sarcoidosis |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 05.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ccm.2023.08.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367358484 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367358484 | ||
| 003 | DE-627 | ||
| 005 | 20240405233420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240121s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ccm.2023.08.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM367358484 | ||
| 035 | |a (NLM)38245360 | ||
| 035 | |a (PII)S0272-5231(23)00075-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ribeiro Neto, Manuel L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiac Sarcoidosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Cardiac involvement is a major cause of morbidity and mortality in patients with sarcoidosis. It is important to distinguish between clinical manifest diseases from clinically silent diseases. Advanced cardiac imaging studies are crucial in the diagnostic pathway. In suspected isolated cardiac sarcoidosis, it's key to rule out alternative diagnoses. Therapeutic options can be divided into immunosuppressive agents, guideline-directed medical therapy, antiarrhythmic medications, device/ablation therapy, and heart transplantation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cardiac sarcoidosis | |
| 650 | 4 | |a Cardiomyopathies | |
| 650 | 4 | |a Heart | |
| 650 | 4 | |a Sarcoidosis | |
| 700 | 1 | |a Jellis, Christine L |e verfasserin |4 aut | |
| 700 | 1 | |a Cremer, Paul C |e verfasserin |4 aut | |
| 700 | 1 | |a Harper, Logan J |e verfasserin |4 aut | |
| 700 | 1 | |a Taimeh, Ziad |e verfasserin |4 aut | |
| 700 | 1 | |a Culver, Daniel A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinics in chest medicine |d 1991 |g 45(2024), 1 vom: 03. März, Seite 105-118 |w (DE-627)NLM012973599 |x 1557-8216 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2024 |g number:1 |g day:03 |g month:03 |g pages:105-118 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ccm.2023.08.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2024 |e 1 |b 03 |c 03 |h 105-118 | ||